<DOC>
	<DOCNO>NCT02014363</DOCNO>
	<brief_summary>To demonstrate antidepressant activity ETS6103 inferior amitriptyline subject unsatisfactory response / resistant treatment SSRIs .</brief_summary>
	<brief_title>Safety Efficacy Study Comparing ETS6103 With Amitriptyline Treatment Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Amitriptyline , perphenazine drug combination</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Signed informed consent Male female Age 1865 year inclusive Subjects current episode moderate severe Major Depressive Disorder meeting criterion Diagnostic Statistical Manual Mental Disorders ( DSM ) IV TR document use brief structure interview Mini International Neuropsychiatric Interview ( MINI ) version 5.0 minimum duration two week maximum twelve month Minimum Hamilton Depression Scale ( HAMD ) 17 item total score 18 screen ≥12 end leadin phase prior randomization . Female subject childbearing potential must negative pregnancy test Screening Visit must use acceptable method contraception throughout study 30 day . Male subject female partner childbearing potential must use acceptable method contraception throughout study 30 day . Able understand comply requirement study judge investigator Considered investigator significant risk suicide score 5 Montgomery Asberg Depression Rating Scale ( c ) question 10 Significant psychiatric illness would interfere trial assessment comorbid generalize anxiety disorder ( GAD ) panic disorder permit MDD consider primary diagnosis Significant physical illness would interfere trial assessment Recent ( within 1 week screen ) antidepressant ( except fluoxetine [ within 4 week screen ] St John 's Wort Monoamine oxidase inhibitor ( MAOI ) [ within 14 day screen ] ) , Benzodiazepine psychotropic medication include lithium mood stabilizer within 1 week screen Oral anticoagulant therapy within one month screen Formal psychotherapy alternative treatment one week prior screen study Reduced hepatic function define liver enzyme level ≥2.5 time upper limit normal Renal insufficiency define creatinine clearance &lt; 30 mL/min Epilepsy Uncontrolled hypothyroidism Uncontrolled hypertension Acute porphyria Urinary retention , prostatic hypertrophy , narrow angle glaucoma increase intraocular pressure clinically relevant contraindication state Summary Product Characteristics ( SmPC ) citalopram , tramadol amitriptyline History significant cardiac dysrhythmia history myocardial infarction within 1 year prior screen Significant history alcohol substance abuse Regular alcohol intake recommend United Kingdom ( UK ) guideline 4 unit per day male 3 unit per day female Pregnant lactate woman Known hepatitis B C human immunodeficiency virus ( HIV ) syphilis seropositivity . A corrected QT interval &gt; 470ms female subject &gt; 450ms male subject , calculate use QTcB ( Bazett Correction Formula ) , second degree high heart block electrocardiography ( ECG ) recording , screen . Allergy study drug excipients Treatment another investigational medicinal product within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>